Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Filip Baert

Showing results (71-80 of 99) with videos related to

Pageof 10
Sort By:
Journal of Crohn'S & Colitis|May 5, 2022
A Narrative Systematic Review and Categorisation of Outcomes in Inflammatory Bowel Disease to Inform a Core Outcome Set for Real-world EvidenceCharlotte Wong, Joep van Oostrom, Peter Bossuyt, et al.
Inflammatory Bowel Diseases|February 28, 2020
Association of Biomarker Cutoffs and Endoscopic Outcomes in Crohn's Disease: A Post Hoc Analysis From the CALM StudyWalter Reinisch, Remo Panaccione, Peter Bossuyt, et al.
Gut|July 10, 2019
Tight control for Crohn's disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trialRemo Panaccione, Jean-Frederic Colombel, Simon P L Travis, et al.
Gastroenterology|June 9, 2019
Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn's DiseaseMark Löwenberg, Severine Vermeire, Nahid Mostafavi, et al.
Journal of Crohn'S & Colitis|December 3, 2010
Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspectsMatthieu Allez, Konstantinos Karmiris, Edouard Louis, et al.
Journal of Crohn'S & Colitis|November 7, 2023
Early Versus Late Use of Vedolizumab in Ulcerative Colitis: Clinical, Endoscopic, and Histological OutcomesSéverine Vermeire, Jurij Hanzel, Mark Löwenberg, et al.
Journal of Clinical Medicine|September 27, 2025
Ustekinumab in Ulcerative Colitis: A Real-Life Effectiveness Study Across Multiple Belgian Centers (SULTAN)Tom Holvoet, Marie Truyens, Catherine Reenaers, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 24, 2024
Rigorous Donor Selection for Fecal Microbiota Transplantation in Active Ulcerative Colitis: Key Lessons From a Randomized Controlled Trial Halted for FutilityClara Caenepeel, Sara Deleu, Jorge Francisco Vazquez Castellanos, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|January 9, 2025
Change in fatigue in patients with ulcerative colitis or Crohn's disease initiating biologic therapyEdouard Louis, Peter Bossuyt, Arnaud Colard, et al.
Frontiers in Pediatrics|February 22, 2021
Health Literacy and Quality of Life in Young Adults From The Belgian Crohn's Disease Registry Compared to Type 1 Diabetes MellitusConstance Carels, Lucas Wauters, An Outtier, et al.
Pageof 10

Showing results (71-80 of 99) with videos related to

Sort By:
Pageof 10
Journal of Crohn'S & Colitis|May 5, 2022
A Narrative Systematic Review and Categorisation of Outcomes in Inflammatory Bowel Disease to Inform a Core Outcome Set for Real-world EvidenceCharlotte Wong, Joep van Oostrom, Peter Bossuyt, et al.
Inflammatory Bowel Diseases|February 28, 2020
Association of Biomarker Cutoffs and Endoscopic Outcomes in Crohn's Disease: A Post Hoc Analysis From the CALM StudyWalter Reinisch, Remo Panaccione, Peter Bossuyt, et al.
Gut|July 10, 2019
Tight control for Crohn's disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trialRemo Panaccione, Jean-Frederic Colombel, Simon P L Travis, et al.
Gastroenterology|June 9, 2019
Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn's DiseaseMark Löwenberg, Severine Vermeire, Nahid Mostafavi, et al.
Journal of Crohn'S & Colitis|December 3, 2010
Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspectsMatthieu Allez, Konstantinos Karmiris, Edouard Louis, et al.
Journal of Crohn'S & Colitis|November 7, 2023
Early Versus Late Use of Vedolizumab in Ulcerative Colitis: Clinical, Endoscopic, and Histological OutcomesSéverine Vermeire, Jurij Hanzel, Mark Löwenberg, et al.
Journal of Clinical Medicine|September 27, 2025
Ustekinumab in Ulcerative Colitis: A Real-Life Effectiveness Study Across Multiple Belgian Centers (SULTAN)Tom Holvoet, Marie Truyens, Catherine Reenaers, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 24, 2024
Rigorous Donor Selection for Fecal Microbiota Transplantation in Active Ulcerative Colitis: Key Lessons From a Randomized Controlled Trial Halted for FutilityClara Caenepeel, Sara Deleu, Jorge Francisco Vazquez Castellanos, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|January 9, 2025
Change in fatigue in patients with ulcerative colitis or Crohn's disease initiating biologic therapyEdouard Louis, Peter Bossuyt, Arnaud Colard, et al.
Frontiers in Pediatrics|February 22, 2021
Health Literacy and Quality of Life in Young Adults From The Belgian Crohn's Disease Registry Compared to Type 1 Diabetes MellitusConstance Carels, Lucas Wauters, An Outtier, et al.
Pageof 10